SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) was the target of a large increase in short interest in the month of June. As of June 30th, there was short interest totaling 636,132 shares, an increase of 141.3% from the June 15th total of 263,601 shares. Based on an average trading volume of 459,329 shares, the short-interest ratio is presently 1.4 days. Currently, 0.8% of the shares of the company are sold short.
Wall Street Analyst Weigh In
SOPH has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. BTIG Research reaffirmed a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a report on Monday, June 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $7.50.
Get Our Latest Research Report on SOPH
SOPHiA GENETICS Price Performance
SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The company had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.
Insiders Place Their Bets
In other SOPHiA GENETICS news, insider Zhenyu Xu sold 7,393 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.17, for a total value of $38,221.81. Following the sale, the insider directly owned 614,887 shares of the company’s stock, valued at approximately $3,178,965.79. This represents a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ross Muken sold 9,838 shares of the stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $5.22, for a total value of $51,354.36. Following the sale, the chief executive officer directly owned 670,651 shares in the company, valued at $3,500,798.22. This represents a 1.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 184,270 shares of company stock worth $999,267. Company insiders own 4.88% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. First Dallas Securities Inc. acquired a new stake in SOPHiA GENETICS in the 1st quarter worth about $50,000. Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS in the third quarter valued at approximately $49,000. Perkins Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS in the fourth quarter worth approximately $49,000. Quadrature Capital Ltd acquired a new stake in shares of SOPHiA GENETICS in the fourth quarter worth approximately $54,000. Finally, XTX Topco Ltd purchased a new stake in shares of SOPHiA GENETICS during the fourth quarter worth approximately $55,000. 31.59% of the stock is owned by hedge funds and other institutional investors.
About SOPHiA GENETICS
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Further Reading
- Five stocks we like better than SOPHiA GENETICS
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
